Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma

INTRODUCTION: Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jun, Yu, Yaner, Zhou, Yangkun, Ji, Qing, Qian, Wenkang, Jia, Dongdong, Jin, Gu, Qi, Yajun, Li, Xin, Li, Ningning, Li, Tao, Fang, Meiyu, Jin, Hongchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632292/
https://www.ncbi.nlm.nih.gov/pubmed/36338718
http://dx.doi.org/10.3389/fonc.2022.942258
Descripción
Sumario:INTRODUCTION: Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM. METHODS: A SNMM patient with ROS1 fusion received 250mg Crizotinib capsule (2 times a day, 1 tablet each time) therapy. RESULTS: The patient achieved partial remission after 4 months of treatment and complete remission after 8 months of treatment. CONCLUSION: Our findings suggest that crizotinib can be an option to improve overall survival and quality of life of patients with metastatic ROS1-fusion SNMM. We believe that our report will provide insights for the application of crizotini in the treatment of melanoma.

Ejemplares similares